Focus is on riminophenazines, a promising but problematic class of compounds.
The Institute of Materia Medica (IMM) and the Global Alliance for TB Drug Development (TB Alliance) reported plans to pursue a joint research partnership to develop promising antituberculosis agents.
“This historic agreement between IMM and the TB Alliance offers hope for scientific advances in the development of critically needed new TB drugs,” comments Xiao-Liang Wang, director of the Institute Materia Medica, a member of the Chinese Academy of Medical Sciences. “In China we know how important it is to develop and deliver novel TB drugs that work more quickly and can help prevent the problems that today’s drugs have with compliance, drug resistance, and TB-HIV co-infection.”
The TB Alliance and IMM will work together on the design, synthesis, and evaluation of a class of compounds known as riminophenazines. It was discovered in the 1950s and developed to work against TB but has not been used due to some side effects. The goal thus is to deliver novel compounds from the riminophenazine class without the side effects to improve TB treatment.